Based on the functionality of c-Met and the clinical efficacy of monoclonal antibody and small-molecule inhibitors, which is meaningful mainly in patients with NSCLC and HCC [5], c-Met has emerged as one of the promising targets for the development of anti-cancer therapeutics against, mainly, HCC and NSCLC. This evidence concerns the gene MET and hepatocellular carcinoma.